HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1

Journal of Gene Medicine

Volumn 8, Issue 1, 2006, Pages 18-28

  Zeng, Lingbing ^a,e   Planelles, Vicente ^b   Sui, Ziye ^c   Gartner, Suzanne ^d   Maggirwar, Sanjay B ^c   Dewhurst, Stephen ^c   Ye, Linbai ^e   Nerurkar, Vivek R ^a   Yanagihara, Richard ^a   Lu, Yuanan ^a,f  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WUHAN UNIVERSITY   (China)

^f Leahi Hospital   (United States)

Author keywords

Blood derived monocytes (BDM); Defective lentiviral vector (DLV); Green fluorescent protein (GFP); HIV 1; Monocots derived macrophages (MDM); Transduction efficiency; Vector mobilization (VM)

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CALCIUM PHOSPHATE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; NEUROTOXIN;

ARTICLE; CELL ADHESION; CELL CULTURE; CELL ISOLATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

CELLS, CULTURED; DEFECTIVE VIRUSES; FEASIBILITY STUDIES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV-1; HUMANS; LENTIVIRUS; MACROPHAGES; MODELS, GENETIC; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; LILIOPSIDA;

EID: 31644435923     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.825     Document Type: Article

References (57)

1. Akkina RK, Walton RM, Chen ML, et al. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996; 70: 2581-2585.
2. Sutton RE, Wu HTM, Rigg R, et al. Human immunodeficiency virus type 1 vectors efficiently transduced human hematopoietic stem cells. J Virol 1998; 72: 5781-5788.
3. + cells with HIV-1-derived lentiviral vectors. Mol Ther 2000; 2: 71-80.
4. Zhang XY, La Russa VF, Bao L, et al. Lentiviral vectors for sustained transgene expression in human bone marrow-derived stromal cells. Mol Ther 2002; 5: 555-565.
5. + cells transduced and selected with a clinically applicable protocol reconstitute lymphopoiesis in SCID-Hu mice. Hum Gene Ther 2004; 15: 305-311.
6. Hong Y, Lee K, Yu SS, et al. Factors affecting retrovirus-mediated gene transfer to human CD34+ cells. J Gene Med 2004; 6: 724-733.
7. Lu X, Humeau L, Slepushkin V, et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med 2004; 6: 963-973.
8. Neil S, Martin F, Ikeda Y, et al. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 2001; 75: 5448-5456.
9. Mordelet E, Kissa K, Calvo CF, et al. Brain engraftment of autologous macrophages transduced with a lentiviral flap vector: an approach to complement brain dysfunctions. Gene Ther 2002; 9: 46-52.
10. Lee MTM, Coburn GA, McClure MO, et al. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expression from a lentivirus vector. J Virol 2003; 77: 11964-11972.
11. Schroers R, Kissa K, Calvo CF, et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther 2000; 1: 171-179.
12. + progenitor cell-derived macrophages. Mol Ther 2003; 8: 62-71.
13. Lu Y, Liu C, Zeng L, et al. Efficient gene transfer into human monocytes-derived macrophages using defective lentiviral vectors. Cell Mol Biol 2003; 49: 115-1156.
14. Buchschacher GL, Wong-stall F. Development of lentiviral vectors for gene therapy for human diseases. Blood 2000; 95: 2499-2504.
15. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of tuning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
16. Nabel GJ. Genetic, cellular and immune approaches to disease the past and future. Nat Med 2004; 10: 135-141.
17. Gartner S, Markovits P, Markovits DM, et al. The role of mononuclear phagocytes in HTLV-III/LAW infection. Science 1986; 233: 215-219.
18. Gendelman HE, Orenstein JM, Martin MA, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988; 167: 1428-1441.
19. Collman R, Hassan NF, Walker R, et al. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1): monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types. J Exp Med 1989; 170: 1149-1163.
20. Dubois-Dalcq M, Altmeyer R, Chiron M, et al. HIV interactions with cells of the nervous system. Curr Opin Neurol 1995; 5: 647-755.
21. Zhu T. HIV-1 genotypes in peripheral blood monocytes. J Leukoc Biol 2000; 68: 338-344.
22. McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virus-associated dementia. Semin Neurol 1999; 19: 129-136.
23. Portegies P, Solod L, Cinque P, et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 2004; 11: 297-304.
24. Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17: 1539-1545.
25. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171-177.
26. Schneider SD, Rusconi S, Seger RA, et al. Adenovirus-mediated gene transfer into monocytes-derived macrophage of patients with X-linked chronic granulomatous disease: ex vivo correction of deficient respiratory burst. Gene Ther 1997; 4: 524-532.
27. Heider H, Verca SB, Rusconi S, et al. Comparison of lipid-mediated and adenoviral gene transfer in human monocyte-derived macrophages and COS-7 cells. Biotechniques 2000; 28: 260-265, 268-270.
28. Liu Y, Santin AD, Mane M, et al. Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J Interferon Cytokine Res 2000; 20: 21-30.
29. Paul S, Bizouarne N, Dott K, et al. Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther 2000; 7: 615-623.
30. Costantini LC, Bakowska JC, Breakefield XO, et al. Gene therapy in the CNS. Gene Ther 2000; 7: 93-109.
31. Ponnazhagan S, Mahendra G, Curiel DT, et al. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 2001;75:9493-9501.
32. Klimatcheva E, Planelles V. Day SL, et al. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol Ther 2001; 3: 928-939.
33. Zhu Y. Feuer G, Day SL, et al. Multigene lentiviral vectors based on differential splicing and translational control. Mol Ther 2001; 4: 375-382.
34. Ramirez SH, Sanchez JF, Dimitri CA, et al. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. J Neurochem 2001; 78:874-879.
35. Maggirwar SB, Tong N, Ramirez S, et al. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 1999; 73: 578-586.
36. Yamagishi S, Matsumoto T, Yokomaku D, et al. Comparison of inhibitory effects of brain-derived neurotrophic factor and insulin-like growth factor on low potassium-induced apoptosis and activation of p38 MAPK and c-Jun in cultured cerebellar granule neurons. Brain Res Mol Brain Res 2003; 119: 184-191.
37. Humeau LM, Binder GK, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mot Ther 2004; 9: 902-913.
38. Azzouz M, Kingsman SM, Mazarakis ND. Lentiviral vectors for treating and modeling human CNS disorders. J Gene Med 2004; 6: 951-962.
39. Triques K, Stevenson M. Characterization of restrictions to human immunodeficiency virus type-1 infection of monocytes. J Virol 2004; 78: 5523-5527.
40. Perry SW, Hamilton JA, Tjoelker LW, et al. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem 1998; 273: 17 660-17 664.
41. Dropulic B, Hermankova M, Pitha PA. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A 1996; 93: 11103-11108.
42. Mautino MR. Lentiviral vectors for gene therapy of HIV-1 infection. Curr Gene Ther 2002; 2: 23-43.
43. Barker E, Planelles V. Vectors derived from human immunodeficiency virus, HIV-1. Front Biosci 2003; 8: 491-510.
44. An DS, Morizono K, Li QX, et al. An inducible HIV vector which effectively suppresses HIV replication. J Virol 1999; 73: 7671-7677.
45. Corbeau P, Wong-Staal F. Anti-HIV effects of HIV vectors. Virology 1998; 243: 268-274.
46. Bukovsky AA, Song JP, Naldini L. Interaction of HIV-derived vectors with wild-type virus in transduced cells. J Virol 1999; 73:7087-7092.
47. Volsky DJ, Simm M, Shahabuddin M, et al. Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4. J Virol 1996;70:3823-3833.
48. Hoglund S, Ohagen A, Goncalves J, et al. Ultrastructure of HIV-1 genomic RNA. Virology 1997; 233: 271-279.
49. Ding SF, Noronha J, Joshi S. Co-packaging of sense and anti-sense RNAs: a novel strategy for blocking HIV-1 replication. Nucleic Acids Res 1998; 26: 3270-3278.
50. Huang L, Bosch I, Hofmann W, et al. Tat protein induces HIV-1 coreceptors and promotes infection with both macrophagetropic and T-lymphotropic HIV-1 strains. J Virol 1998; 72: 8952-8960.
51. Li CJ, Ueda Y, Shi B, et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci U S A 1997; 94:8116-8120.
52. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375: 497-500.
53. Maldarelli F, Chen MY, Willey RL, et al. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol 1993; 67: 5056-5061.
54. Willey RL, Maldarelli F, Martin MA, et al. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992; 66: 7193-7200.
55. Margottin F, Bour SP, Durand H, et al. Novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998; 1: 565-574.
56. Freed EO, Martin MA. HIVs and their replication. In Fields Virology, Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins: Baltimore, 2001; 1971-2094.
57. Nishitsuji H, Ikeda T, Miyoshi H, et al. Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. Microbes Infect 2004; 6: 76-85.